Search

everythinglearnresearchcommunity

for

Search:↓

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

CS12192 effectively treats alopecia areata with better safety than current options.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Upadacitinib improved multiple immune-related conditions in one patient.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.